🚀 VC round data is live in beta, check it out!
Bausch + Lomb Valuation Multiples
Discover revenue and EBITDA valuation multiples for Bausch + Lomb and similar public comparables like Abbott India, Getinge, Teleflex, Caris Life Sciences and more.
Bausch + Lomb Overview
About Bausch + Lomb
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.
Founded
2020
HQ
Employees
13.0K
Website
Financials (LTM)
EV
$11B
Bausch + Lomb Financials
Bausch + Lomb reported last 12-month revenue of $5B and EBITDA of $929M.
In the same LTM period, Bausch + Lomb generated $3B in gross profit, $929M in EBITDA, and $214M in net income.
Revenue (LTM)
Bausch + Lomb P&L
In the most recent fiscal year, Bausch + Lomb reported revenue of $5B and EBITDA of $891M.
Bausch + Lomb expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $5B | XXX | $5B | XXX | XXX | XXX |
| Gross Profit | $3B | XXX | $3B | XXX | XXX | XXX |
| Gross Margin | 61% | XXX | 60% | XXX | XXX | XXX |
| EBITDA | $929M | XXX | $891M | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 17% | XXX | XXX | XXX |
| EBIT Margin | 12% | XXX | 12% | XXX | XXX | XXX |
| Net Profit | $214M | XXX | $182M | XXX | XXX | XXX |
| Net Margin | 4% | XXX | 4% | XXX | XXX | XXX |
| Net Debt | — | — | $5B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Bausch + Lomb Stock Performance
Bausch + Lomb has current market cap of $6B, and enterprise value of $11B.
Market Cap Evolution
Bausch + Lomb's stock price is $16.55.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $11B | $6B | -1.9% | XXX | XXX | XXX | $0.51 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBausch + Lomb Valuation Multiples
Bausch + Lomb trades at 2.0x EV/Revenue multiple, and 11.4x EV/EBITDA.
EV / Revenue (LTM)
Bausch + Lomb Financial Valuation Multiples
As of April 21, 2026, Bausch + Lomb has market cap of $6B and EV of $11B.
Equity research analysts estimate Bausch + Lomb's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Bausch + Lomb has a P/E ratio of 27.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6B | XXX | $6B | XXX | XXX | XXX |
| EV (current) | $11B | XXX | $11B | XXX | XXX | XXX |
| EV/Revenue | 2.0x | XXX | 2.1x | XXX | XXX | XXX |
| EV/EBITDA | 11.4x | XXX | 11.9x | XXX | XXX | XXX |
| EV/EBIT | 16.7x | XXX | 17.8x | XXX | XXX | XXX |
| EV/Gross Profit | 3.3x | XXX | 3.5x | XXX | XXX | XXX |
| P/E | 27.6x | XXX | 32.4x | XXX | XXX | XXX |
| EV/FCF | 70.4x | XXX | 1811.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Bausch + Lomb Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Bausch + Lomb Margins & Growth Rates
Bausch + Lomb's revenue in the last 12 month grew by 7%.
Bausch + Lomb's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.
Bausch + Lomb's rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Bausch + Lomb's rule of X is 37% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Bausch + Lomb Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 18% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Growth | 14% | XXX | 14% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 26% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 37% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| R&D Expenses to Revenue | 7% | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 56% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Bausch + Lomb Public Comps
See public comps and valuation multiples for other Health & Beauty and Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Bausch + Lomb | XXX | XXX | XXX | XXX | XXX | XXX |
| Abbott India | XXX | XXX | XXX | XXX | XXX | XXX |
| Getinge | XXX | XXX | XXX | XXX | XXX | XXX |
| Teleflex | XXX | XXX | XXX | XXX | XXX | XXX |
| Caris Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Asahi Intecc | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Bausch + Lomb M&A Activity
Bausch + Lomb acquired XXX companies to date.
Last acquisition by Bausch + Lomb was on XXXXXXXX, XXXXX. Bausch + Lomb acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Bausch + Lomb
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBausch + Lomb Investment Activity
Bausch + Lomb invested in XXX companies to date.
Bausch + Lomb made its latest investment on XXXXXXXX, XXXXX. Bausch + Lomb invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Bausch + Lomb
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Bausch + Lomb
| When was Bausch + Lomb founded? | Bausch + Lomb was founded in 2020. |
| Where is Bausch + Lomb headquartered? | Bausch + Lomb is headquartered in Canada. |
| How many employees does Bausch + Lomb have? | As of today, Bausch + Lomb has over 13K employees. |
| Who is the CEO of Bausch + Lomb? | Bausch + Lomb's CEO is Brenton L. Saunders. |
| Is Bausch + Lomb publicly listed? | Yes, Bausch + Lomb is a public company listed on NYSE. |
| What is the stock symbol of Bausch + Lomb? | Bausch + Lomb trades under BLCO ticker. |
| When did Bausch + Lomb go public? | Bausch + Lomb went public in 2022. |
| Who are competitors of Bausch + Lomb? | Bausch + Lomb main competitors are Abbott India, Getinge, Teleflex, Caris Life Sciences. |
| What is the current market cap of Bausch + Lomb? | Bausch + Lomb's current market cap is $6B. |
| What is the current revenue of Bausch + Lomb? | Bausch + Lomb's last 12 months revenue is $5B. |
| What is the current revenue growth of Bausch + Lomb? | Bausch + Lomb revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Bausch + Lomb? | Current revenue multiple of Bausch + Lomb is 2.0x. |
| Is Bausch + Lomb profitable? | Yes, Bausch + Lomb is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Bausch + Lomb? | Bausch + Lomb's last 12 months EBITDA is $929M. |
| What is Bausch + Lomb's EBITDA margin? | Bausch + Lomb's last 12 months EBITDA margin is 18%. |
| What is the current EV/EBITDA multiple of Bausch + Lomb? | Current EBITDA multiple of Bausch + Lomb is 11.4x. |
| What is the current FCF of Bausch + Lomb? | Bausch + Lomb's last 12 months FCF is $151M. |
| What is Bausch + Lomb's FCF margin? | Bausch + Lomb's last 12 months FCF margin is 3%. |
| What is the current EV/FCF multiple of Bausch + Lomb? | Current FCF multiple of Bausch + Lomb is 70.4x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.